KNSA Kiniksa Pharmaceuticals Earnings and EPS analysis

Relative Growth: Rel. Growth: 94

Relative Strength: Rel. Strength: 74

Relative Valuation: Rel. Valuation: 53

Relative Profitability: Rel. Profitability: 96

EPS in 2026 (TTM): $0.98

Last Report Period Date: Mar 31, 2026

As of June 2026, KNSA's current EPS stands at $0.98, according to the latest financial reports. For the year 2025, the company recorded an earnings per share (EPS) of $0.8, which marks an increase compared to its EPS of -$0.6 in 2024. KNSA reported an EPS of $0.3 for the quarterly report ending on Mar 31, 2026.

KNSA earnings history

Historical annual and quarterly earnings per share (EPS) data for Kiniksa Pharmaceuticals

EPS (TTM)

$0.98

EPS Growth YoY (Quarterly)

150%

EPS (Quarterly)

$0.3

EPS Growth (Quarterly)

57.9%

For 2025, Kiniksa Pharmaceuticals's EPS was $0.8, an increase of 233.3% from -$0.6 in 2024. For the fiscal quarter that ended on Mar 31, 2026, the per-share earnings was $0.3, showing a 150% increase from the same quarter last year. For the twelve months ending March 2026, the EPS is $0.98. For the year 2024, the yearly earnings per share was -$0.6, marking a decrease of 400% from 2023.

KNSA earnings chart

KNSA EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

150%

EPS growth YoY

233.3%

EPS growth 3Y avg

-32.8%

EPS growth 5Y avg

N/A

During the last 12 months, Kiniksa Pharmaceuticals has seen an EPS growth of 150% (YoY, quarterly). Throughout the last three years, the company had an average EPS growth of -32.8% per year.

KNSA Earnings Waterfall

Breakdown of revenue, profit and net income for Kiniksa Pharmaceuticals

KNSA Earnings vs Peers

What are the earnings of KNSA compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
VIVS VivoSim Labs Inc.	0.77	91.2%	N/A	N/A
ORMP Oramed Pharmaceuticals Inc	1.44	418.8%	N/A	N/A
OMER Omeros Corp	7.88	98.1%	N/A	N/A
KNSA Kiniksa Pharmaceuticals Ltd	50.33	233.3%	-32.8%	N/A
OLMA Olema Pharmaceuticals Inc	N/A	15%	N/A	N/A
ORIC Oric Pharmaceuticals Inc	N/A	19.7%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.